The Chinese gene-editing experiment was an outrage. The scientific community shares blame.
By J. Benjamin Hurlbut, Sheila Jasanoff and Krishanu Saha,
The Washington Post
| 11. 29. 2018
This is the experiment that was not supposed to happen.
A Chinese scientist claimed this week that he had produced the first genetically engineered babies — twin girls who have been “edited” to be resistant to HIV. He and his collaborators, who apparently include a professor at Rice University in Houston, allegedly applied the genome editing tool known as CRISPR to embryos produced through in vitro fertilization to modify a gene called CCR5. The purpose of the edit was to prevent future HIV infection, a move akin to a genetic vaccination.
Three years ago, scientists, social scientists and ethicists gathered in Washington at the National Academy of Sciences for the first international summit on human gene editing, to discuss scientific, social and ethical issues surrounding human applications of this powerful new tool. One result of the meeting was a call for a voluntary international moratorium on reproductive applications of genome editing until there was “broad societal consensus” about when making such heritable modifications is ethically acceptable.
Nothing remotely like a consensus has been reached, yet the research races ahead. Numerous...
Related Articles
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...